January 4, 2018 Foamix Announces Positive Results from Phase 3 Open-Label Safety Extension Evaluating FMX-101 Topical Minocycline Foam for Treatment up to 1 Year View Article
June 29, 2017 Foamix Pharmaceuticals Appoints David Domzalski as Chief Executive Officer View Article
May 1, 2017 Foamix Pharmaceuticals Announces Plans for Additional Phase 3 Trial for FMX101 in Moderate to Severe Acne View Article
